Hyperion’s Glycerol Phenylbutyrate Meets Primary Endpoint

Hyperion Therapeutics, Inc. Tuesday announced that the company’s phase III pivotal study of glycerol phenylbutyrate, an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.
CNBC